Neurocrine Biosciences, Inc.
NBIX
Clasificación en acciones
#1552
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Precio por acción
$140.48
Capitalización bursátil
$14.28B
Cambio (1 día)
2.56%
Cambio (1 año)
-0.60%
País
US
Comercio Neurocrine Biosciences, Inc. (NBIX)
Categoría
Healthcare
Ganancias de Neurocrine Biosciences, Inc. (NBIX)
Ganancias en Jun 2026 TTM: $940.20M
Secondo gli ultimi rapporti finanziari di Neurocrine Biosciences, Inc., gli utili attuali della società sono $940.20M. Nel 2024, la società ha registrato un utile di $486.00M, un aumento con respecto a agli utili del 2023, che erano di $332.10M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Neurocrine Biosciences, Inc. desde 2000 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $940.20M | 33.29% |
| 2025 | $705.40M | 45.14% |
| 2024 | $486.00M | 46.34% |
| 2023 | $332.10M | 55.26% |
| 2022 | $213.90M | 110.95% |
| 2021 | $101.40M | -4.97% |
| 2020 | $106.70M | 129.46% |
| 2019 | $46.50M | 112.90% |
| 2018 | $21.84M | -115.32% |
| 2017 | $-142.54M | 1.03% |
| 2016 | $-141.09M | 58.65% |
| 2015 | $-88.93M | 46.89% |
| 2014 | $-60.54M | 31.36% |
| 2013 | $-46.09M | -1,017.21% |
| 2012 | $5.03M | -86.63% |
| 2011 | $37.57M | -571.52% |
| 2010 | $-7.97M | -91.01% |
| 2009 | $-88.61M | 0.00% |
| 2008 | $-88.61M | -57.25% |
| 2007 | $-207.30M | 93.37% |
| 2006 | $-107.21M | 383.10% |
| 2005 | $-22.19M | -51.44% |
| 2004 | $-45.69M | 51.82% |
| 2003 | $-30.10M | -68.16% |
| 2002 | $-94.54M | 156.96% |
| 2001 | $-36.79M | 29.06% |
| 2000 | $-28.51M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | 461.04% |
US
|
|
| $-3.09B | -428.33% |
US
|
|
| $-4.02B | -527.16% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 107.47% |
NL
|
